Showing results (561-570 of 3,079) with videos related to
Sort By:
Pageof 308
Drug Safety|January 23, 2016
Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for PharmacoepidemiologyChristian Hampp, Patty Greene, Simone P PinheiroDrug Safety|February 11, 2016
Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 ParticipantsHaixia Li, Cailian Wang, Shuo Zhang, et al.Drug Safety|February 14, 2016
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical CasesAnnamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, et al.Drug Safety|March 7, 2016
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event ReportsKeith B Hoffman, Mo Dimbil, Nicholas P Tatonetti, et al.Drug Safety|August 13, 2015
Experiences and Lessons From Implementing Cohort Event Monitoring Programmes for Antimalarials in Four African Countries: Results of a Questionnaire-Based SurveyComfort Kunak Suku, Geraldine Hill, George Sabblah, et al.Drug Safety|December 8, 2014
Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?Supriya Mathur, Nicola N Zammitt, Brian M FrierDrug Safety|January 9, 2015
Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) projectKatherine C Allen, Amanda H Champlain, Jonathan A Cotliar, et al.Drug Safety|January 6, 2015
Treating severe malaria in pregnancy: a review of the evidenceStephanie D Kovacs, Marcus J Rijken, Andy StergachisDrug Safety|January 8, 2015
Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilanceDeborah Layton, Saad A W ShakirDrug Safety|October 30, 2014
Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challengesJohn R SeniorPageof 308